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Short abstract: 
The chronic complications of diabetes in humans include cardiomyopathy, neuropathic 
pain, cataract development and retinopathy. The rat is the most commonly used model of 
human disease. This study has determined whether chronic diabetes induced by 
streptozotocin in rats mimics the complications associated with human diabetes.  
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Abstract: 
 
Background: Diabetes in humans induces chronic complications such as cardiovascular 
damage, cataracts and retinopathy, nephropathy and polyneuropathy. The most common 
animal model of human diabetes is streptozotocin(STZ)-induced diabetes in the rat.  
Methods: This project has assessed cardiovascular, ocular and neuropathic changes over a 
period of 24 weeks post-STZ treatment in rats.  
Results: STZ-diabetic rats (n=96) showed stable signs of diabetes (hyperglycaemia, 
increased water and food intake with no increase in body weight); 52% of untreated STZ-
diabetic rats (n=50) survived 24 weeks. STZ-diabetic rats were normotensive with slowly 
developing systolic and diastolic dysfunction and an increased ventricular stiffness. 
Ventricular action potential durations were markedly prolonged. STZ-diabetic rats 
developed stable tactile allodynia. Cataracts developed to presumed blindness at 16 
weeks but proliferative retinopathy was not observed even after 24 weeks.  
Conclusion: The chronic STZ-diabetic rat mimics many but not all of the chronic 
complications observed in the diabetic human. The chronic STZ-diabetic rat may be a 
useful model to test therapeutic approaches for amelioration of chronic diabetic 
complications in humans.  
 
 
 
Introduction 
 
Glucose is the major energy source of cells. A stable blood glucose is necessary since 
energy must be supplied to all cells at all times despite intermittent food intake and 
variable demands, such as the level of physical activity. The major regulatory hormone 
for intermediary metabolism is insulin, produced and secreted by the β-cells of the islets 
of Langerhans of the pancreas. Impaired control of blood glucose concentrations by 
insulin leads to diabetes mellitus. In patients with diabetes, an increased blood glucose 
concentration (hyperglycaemia) causes an increased thirst, hunger and urine volume, but 
it is the chronic complications of diabetes that are the major health issues 1-6.  
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 Diabetes is reaching epidemic proportions in developed countries 7. Estimations suggest 
that diabetes affects about 6% of the population in the USA or 12-15 million people, with 
up to half being undiagnosed 8,9. The prevalence of diabetes increases with age with up to 
25-30% of the elderly suffering from the condition and another 10-25% having impaired 
glucose tolerance 10. For many patients, diabetes is only diagnosed and aggressively 
treated when one of characteristic diabetic complications develops. These include 
cataracts and retinopathy which lead to blindness, impaired kidney function leading to 
end-stage renal disease, diabetic neuropathy which may lead to tactile allodynia, ulcers or 
amputations, macrovascular disease such as atherosclerosis and impotence, or heart 
disease and stroke. In humans, diabetes is associated with long-term cardiovascular 
damage (especially endothelial dysfunction, fibrosis and cardiomyopathy) with a much 
higher risk of coronary artery disease, heart failure, myocardial infarction and death 11.  
 
Diabetes can be induced by selective destruction of the insulin-producing β-cells of the 
pancreas with a single, rapid injection of streptozotocin (STZ), a glucose moiety with a 
very reactive nitrosourea group from the mould Streptomyces griseus. This procedure, 
first introduced in 1963, has since been used in over 7600 PubMed citations, probably 
making this the second most used animal model of human disease after the spontaneously 
hypertensive rat (SHR); cardiovascular changes following streptozotocin have been 
reviewed previously 11. STZ doses of 50-65 mg/kg lead to hyperglycaemia (20-30 mM) 
but severe ketosis does not develop even if insulin is not administered. Higher doses (75 
mg/kg and above) result in spontaneous ketosis and death within days if insulin is not 
given.  
 
Most investigations using STZ-diabetic rats have followed the course of the condition for 
4-6 weeks, sometimes 8 weeks. However, few studies have extended their measurement 
period to 24 weeks which is necessary to study the mechanisms of the chronic 
complications of diabetes such as neuropathy 12,13, retinopathy 14 and nephropathy 15. 
Since human diabetics have a markedly increased morbidity and mortality due to 
cardiovascular disease 1,2, we emphasise in this report the chronic changes in the 
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cardiovascular system that accompany chronic STZ-induced diabetes in the rat. A 
comparison with the chronic changes in human diabetes will indicate whether the STZ-
diabetic rat is an adequate model of the human disease.    
 
Methods 
 
Diabetes was induced in 8 week old male Wistar rats (n=96) using a single rapid injection 
of streptozotocin (STZ; 65 mg/kg) 16 into the femoral vein. The success rate of inducing 
diabetes (defined as a blood glucose concentration ≥15 mM and a water intake of >100 
ml/day at 7 days) was approximately 90%. Insulin was not administered. All control age-
matched male Wistar rats (n=10) survived the 24 week period; 52% of STZ-diabetic rats 
(n=50) survived 24 weeks after STZ injection. Food and water intakes and body weight 
were measured daily for 24 weeks. Blood glucose concentrations were monitored every 
four weeks by a Precision Q.I.D kit; values ≥ 15 mM were considered diabetic. Systolic 
blood pressure was measured every four weeks by a tail-cuff method 17. 
Echocardiography was performed every four weeks to non-invasively assess left 
ventricular size, wall thickness and systolic function 18.  
 
Cardiac contractility, relaxation and stiffness were measured using the isolated 
Langendorff heart preparation 19. A latex balloon catheter was inserted into the left 
ventricle for measurement of isovolumic left ventricular function via connection to a 
disposable pressure transducer (MLT1010) linked to a PowerLab system. Hearts were 
paced at 250bpm by attaching two electrodes to the surface of the right atria. End 
diastolic pressure was initially set to 5 mmHg by balloon inflation and all hearts received 
an equilibration period of approximately 25 minutes. End-diastolic pressure was 
measured for 3 minutes at 5mmHg increments beginning at 0mmHg up to a maximum of 
30mmHg. Measurements of diastolic pressure and systolic pressure were made after 2 
minutes of each 3 minute recording for further calculation of diastolic stiffness and left 
ventricular developed pressure. Myocardial diastolic stiffness was defined by the stiffness 
constant (k, dimensionless), the slope of the linear relation between the tangent elastic 
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modulus (E, dyne/cm2) and stress (σ, dyne/cm2) 19. At the end of the experiment, the atria 
were removed and the weight of the ventricles plus septum was recorded. 
 
Conventional microelectrode techniques were applied to the left ventricular papillary 
muscles to record action potential duration 20. A stainless steel hook was placed in one 
end of the papillary muscle fixed at the other end with a small stainless steel pin 
embedded into a rubber base. The hook was attached to a modified sensor element 
(SensoNor AE801) connected to an amplifier (World Precision Instruments, TBM-4). 
The muscle was slowly stretched to maximum preload over one minute. Contractions 
were induced by field stimulation (Grass SD-9) via electrodes on either side of the 
muscle (stimulation frequency 1 Hz, pulse width 0.5 msec; stimulus strength 20% above 
threshold). After maximum preload was attained, the muscle was allowed to equilibrate 
for a further 45 min before impalement with a glass microelectrode (World Precision 
Instruments, filamented borosilicate glass, outer diameter 1.5 mm) which had a tip 
resistance of 5-15 mΩ when filled with 3 M KCl. The reference electrode was an 
Ag/AgCl electrode. A Cyto 721 electrometer  (World Precision Instruments) was used to 
record bioelectrical activity. All signals were recorded via an Analogue Digital Converter 
(MacLab4S) connected to a Power PC G3. Data were acquired, derived and analysed 
using MacLab4S Chart 4.0 software (AD Instruments). Continual impalement throughout 
an experiment was not always possible. However, if displacement occurred, then the 
results of a subsequent impalement were accepted provided the data fitted the above 
criteria. 
 
Collagen deposition in the heart was visualised following picrosirius red staining 16,17 and 
quantified using laser confocal microscopy.  
 
Calibrated Von Frey filaments 21 were used for weekly assessment of the development 
and maintenance of tactile allodynia in the hindpaws of diabetic relative to non-diabetic 
rats. Von Frey filaments of varying tensile strength (2 – 20g) were applied to the plantar 
surface of the hindpaw of the rat in ascending order of force, until there was a brisk paw 
withdrawal response. If the rat failed to withdraw its paw, a response of 20 g was 
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recorded. Higher forces were not used in order to prevent tissue damage to the footpad of 
the rat.  
 
Every 4 weeks, rats were lightly anaesthetised for assessment of cataract genesis by 
examination of the rat lens magnified x36 with a slit-lamp biomicroscope. Tropicamide 
(1% solution) was administered to the eyes to dilate the pupils so as to give a clear view 
of the lens. Cellufresh® eye drops (carmellose sodium) were administered periodically to 
avoid drying of the cornea. Rat lens cataracts were graded using a grading scale: 0, 
normal clear lens; 1, visible posterior sutures; 2, isolated vacuoles; 3, coalescing 
peripheral vacuoles; 4, radial streaks and dense central opacities 22. Rat retinae were 
isolated at 24 weeks for histochemical evaluation using a diaminobenzidine and glucose 
oxidase staining procedure for blood vessels.  
 
Data are presented as mean ± SEM. Comparisons of the groups was made using the 
unpaired Student’s t test; p<0.05 was considered significant.  
 
 
Results 
 
STZ treatment rapidly produced the characteristic signs of diabetes such as increased 
intake of both water and food, failure to gain weight and increased blood glucose 
concentrations; these changes were maintained for the 24 weeks of observation (figure 1). 
As in humans, untreated diabetes in rats increases mortality as only 52% of STZ-diabetic 
rats survived 24 weeks of diabetes.  
 
Systolic blood pressure remained normal in STZ-treated rats for the full 24 weeks with 
mean systolic blood pressure measurements between 100 and 120 mmHg in both control 
and STZ-diabetic rats. Non-invasive measurement of left ventricular dimensions showed 
decreased wall thickness and increased internal diameter after 24 weeks only (figure 2). 
Systolic function using fractional shortening as an estimate was unchanged. Diastolic 
function was assessed as the ratio of the initial mitral inflow (maximal E wave velocity) 
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to the second mitral inflow (maximal A wave velocity) 18. Using this parameter, diastolic 
function was significantly decreased 24 weeks after STZ treatment (figure 2). Both 
contractility (dP/dt) and relaxation (-dP/dt) were impaired in the isolated hearts of STZ 
rats when measured in the perfused Langendorff heart preparation (figure 3). Further, the 
diastolic stiffness of STZ rat hearts was increased after 24 weeks (control: 0 week, 
20.6±2.0; 12 week, 23.4±0.9; 24 week, 24.6±1.3; STZ-diabetic: 12 week, 24.6±1.3; 24 
week, 32.7±2.1). In addition, STZ treatment was associated with a markedly prolonged 
action potential duration (APD at 20, 50 or 90% repolarisation in msec) measured at all 
stages of repolarization (12 week rats: control, APD20 7.1±0.7; STZ, APD20 17.7±2.2; 
control, APD50 15.1±1.2; STZ, APD50 34.3±4.0; control APD90 38.7±1.9; STZ, APD90 
77.1±6.6; 24 week rats: control, APD20 6.4±0.9; STZ, APD20 21.7±4.6; control, APD50 
13.0±2.1; STZ, APD50 43.8±8.3; control, APD90 29.0±3.7; STZ, APD90 101.0±13.8). 
The resting membrane potential was significantly less depolarised in papillary muscles 
from STZ-treated rats (control –72.3±0.7 mV; STZ –67.5±0.5 mV; n=6). 
 
In control rats (n=6), von Frey testing gave values of 14±0.6g, 14.9±0.7g and 15.6±0.7g 
after 0, 12 and 24 weeks. Tactile allodynia developed in STZ-diabetic rats (n=14) after 7-
10 days and reached a maximum after 2 weeks; this persisted unchanged for 24 weeks (0 
weeks, 14.7±0.6g; 12 weeks, 7.4±0.5g; 24 weeks, 6.4±1.0g). Bilateral cataracts 
developed early, with lens changes in the form of posterior streak opacities observed at 4 
weeks in STZ-treated rats. Cataract development was progressive with severe cataracts 
with presumed blindness in all eyes 16 weeks post-treatment (figure 4) while vascular 
changes were less pronounced, even after 24 weeks, with no significant differences in 
vessel numbers between normal and diabetic rats. However, ghost or loop-like vessels as 
well as microaneurysm formation was evident in retinas from STZ-treated rats (figure 5).  
 
Discussion 
 
Our studies on the chronic STZ-diabetic rat show that this model reliably produces many 
of the signs and symptoms of chronic human diabetes, in particular diastolic cardiac 
dysfunction, cataracts and neuropathy. An important difference is that rats do not develop 
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atherosclerosis and remain normotensive unlike human diabetics, at least over a 24 week 
observation period. However, these characteristics of the chronic STZ-diabetic rat allow 
investigation of hyperglycaemia-induced changes which are independent of the 
development of atherosclerosis and hypertension.  
 
Diabetes in humans is characterised by a progressive accumulation of complications 
which markedly increase morbidity and mortality. In both type 1 and type 2 diabetics, 
cardiovascular disease, especially coronary artery disease due to atherosclerosis, remains 
the major cause of this increase with a 2-3 fold increase over age- and gender-matched 
non-diabetic patients 1-3. However, there are important contributions from chronic renal, 
ocular and nerve damage. In a 10-year study of type 2 diabetics, 38% developed 
microalbuminuria as a symptom of nephropathy 4 while 55% had signs of retinopathy 5. 
Polyneuropathy is also an insidious complication of diabetes affecting about 42% of type 
2 diabetics 10 years after diagnosis 6. Understanding the basis for these complications 
requires an animal model of chronic diabetes that mimics the changes observed in 
humans.  
 
Hypertension, obesity, dyslipidaemia, microalbuminuria, endothelial dysfunction, 
autonomic neuropathy and diabetic cardiomyopathy are amongst the many factors that 
contribute to the high prevalence of cardiovascular disease in human diabetes 1,2. STZ-
diabetic rats slowly developed both diastolic dysfunction and systolic dysfunction as 
shown in vivo by echocardiography and also in the isolated heart. The diastolic stiffness 
was also increased in the isolated heart, consistent with an increased collagen deposition 
16. Fibrosis of the myocardium may be associated with inefficient conduction of cardiac 
pacemaker electrical impulses resulting in arrhythmia. Further, STZ-diabetic rats have a 
significant increase in duration of action potential in all phases of repolarisation possibly 
due to a reduction in the transient outward potassium current and the inward calcium 
current 23.  
 
The STZ-diabetic rat models diabetic neuropathy due to the similarities of the structural, 
functional and biochemical abnormalities in the periphery to human diabetic patients 22. 
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This study has extended this to the progression of tactile allodynia and painful diabetic 
neuropathy in chronic diabetes.  
 
Glucose-stressed lens have increased oxidative stress or reduced ability to remove 
reactive oxygen species or both. Ten- to twenty-fold increases in sorbitol concentration in 
the lenses due to membrane impermeability and slow conversion to fructose may lead to 
increased osmotic stress or an erosion of the components required to counter such stress 
22. This study demonstrated that the development of senile cataracts in diabetic lenses was  
rapid and severe especially considering the lack of cataract development in age-matched 
control lenses. 
 
Early degeneration of the endothelium by free radical damage, production of AGEs 
(advanced glycation end-products) and hypersecretion of various basement membrane 
proteins may affect transport, permeability and integrity of tight junctions and the blood-
retinal barrier 24. This leads to increased capillary leakage as well as microaneurysms 
which compromises blood and nutrient flow in the retina, causing an ischaemic state. A 
low oxygen tension stimulates VEGF (vascular endothelial growth factor) synthesis and 
VEGF receptor expression in an attempt to revascularise the ischaemic retina. Despite 
this, retinal vascular proliferation is a rare occurrence in animal models of diabetes 25, as 
observed in this study. However, we observed the formation of numerous 
microaneurysms and ghost vessels as well as loop-like vessels, all of which are indicative 
of progression towards proliferative retinopathy. This suggests that retinopathy does 
occur and vascular proliferation would be observed if the measurement period could be 
extended. 
  
The incidence and severity of chronic complications in diabetic humans necessitates 
therapeutic interventions. The chronic STZ-diabetic rat has been used for testing the 
effects of novel pharmacological agents, for example troglitazone in neuropathy 12 and 
ramipril or valsartan in nephropathy 15. These chronic studies should provide useful 
options for testing therapeutic approaches to ameliorate chronic diabetic complications in 
humans.  
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 In conclusion, these results indicate that the chronic STZ-diabetic rat mimics many but 
not all of the chronic complications observed in the diabetic human.  
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Legends to figures 
 
Figure 1: Water (A) and food (B) consumption, body weight (C) and blood glucose 
concentration (D) in control (open circles) and STZ-treated rats (closed circles); n=10 
(control) and 37 (STZ-treated) for water and food consumption and body weight; n=10 
(control) and 20 (STZ-treated) for glucose measurements; *p<0.05 vs control. 
 
Figure 2: Ventricular dimensions and function as derived from echocardiography in 
control (open circles) and STZ-treated rats (closed circles): left ventricular wall thickness 
(A) and internal diameter (B), % fractional shortening (C) and maximal mitral E/A flow 
ratio (D); n=11 (controls) and 10 (STZ-treated rats) except for (D) where n=8 (control) 
and 6 (STZ-treated); *p<0.05 vs control.  
 
Figure 3: dP/dt (circles) and –dP/dt values (squares) in isolated Langendorff heart 
preparations from control rats (open symbols; n=7) and STZ-treated rats (closed symbols) 
after 12 weeks (n=9) and 24 weeks (n=7); *p<0.05 vs control. 
 
Figure 4: Cataract grade in lenses of control rats (n=6; open circles) and of rats for up to 
24 weeks after STZ-treatment (n=6; closed circles); *p<0.05 vs control.  
 
Figure 5: Retinal blood vessels in a rat 24 weeks after STZ treatment (x20 
magnification); loop-like vessels are shown by a blue arrow, microaneurysms are shown 
by a green arrow and ghost vessels are shown by a red arrow.  
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